Drug permeation across intestinal epithelial cells using porous silicon nanoparticles

Biomaterials

Volumn 32, Issue 10, 2011, Pages 2625-2633

  Bimbo, Luis M ^a   Mäkilä, Ermei ^b   Laaksonen, Timo ^a   Lehto, Vesa Pekka ^c   Salonen, Jarno ^b   Hirvonen, Jouni ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cytotoxicity; Degradation; Epithelial cell; Macrophage; Nanoparticle; Silicon

Indexed keywords

CACO-2 CELLS; CELL VIABILITY; DELIVERY PROCESS; DIFFERENT SIZES; DRUG PERMEATION; EPITHELIAL CELLS; INTESTINAL EPITHELIAL CELLS; MESOPOROUS SILICON; NANOSIZED MATERIALS; PARENTERAL ADMINISTRATION; PHYSIOLOGICAL ENVIRONMENT; POORLY SOLUBLE DRUGS; POROUS NANOPARTICLES; REACTIVE OXYGEN SPECIES; SILICON NANOPARTICLES; SIZE DEPENDENT; THERMALLY OXIDIZED; TRANSMISSION ELECTRON MICROSCOPE;

BEHAVIORAL RESEARCH; BIOMATERIALS; DEGRADATION; MACROPHAGES; MICROCRYSTALS; MONOLAYERS; NANOPARTICLES; NITRIC OXIDE; OXYGEN; TRANSMISSION ELECTRON MICROSCOPY;

POROUS SILICON;

GRISEOFULVIN; NANOPARTICLE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SILICON; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG PENETRATION; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; NONHUMAN; POROSITY; PRIORITY JOURNAL;

ANIMALS; CACO-2 CELLS; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; EPITHELIAL CELLS; GRISEOFULVIN; HUMANS; INFLAMMATION; INTESTINES; INTRACELLULAR SPACE; MACROPHAGES; MICE; NANOPARTICLES; NITRIC OXIDE; OXIDATION-REDUCTION; POROSITY; REACTIVE OXYGEN SPECIES; SILICON; SOLUBILITY; TEMPERATURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79251597323     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.12.011     Document Type: Article

References (48)

1. Vasconcelos T., Sarmento B., Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007, 12(23-24):1068-1075.
2. Kesisoglou F., Panmai S., Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007, 59(7):631-644.
3. Brayden D.J. Controlled release technologies for drug delivery. Drug Discov Today 2003, 8(21):976-978.
4. Colombo P., Sonvico F., Colombo G., Bettini R. Novel platforms for oral drug delivery. Pharm Res 2009, 26(3):601-611.
5. Anglin E.J., Cheng L., Freeman W.R., Sailor M.J. Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev 2008, 60(11):1266-1277.
6. Salonen J., Kaukonen A.M., Hirvonen J., Lehto V.P. Mesoporous silicon in drug delivery applications. J Pharm Sci 2008, 97(2):632-653.
7. Prestidge C.A., Barnes T.J., Lau C.H., Barnett C., Loni A., Canham L. Mesoporous silicon: a platform for the delivery of therapeutics. Expert Opin Drug Deliv 2007, 4(2):101-110.
8. Low S.P., Voelcker N.H., Canham L.T., Williams K.A. The biocompatibility of porous silicon in tissues of the eye. Biomaterials 2009, 30(15):2873-2880.
9. Canham L.T. Bioactive silicon structure fabrication through nanoetching techniques. Adv Mater 1995, 7(12):1033-1037.
10. Salonen J., Laitinen L., Kaukonen A.M., Tuura J., Bjorkqvist M., Heikkila T., et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release 2005, 108(2-3):362-374.
11. Wang F., Hui H., Barnes T.J., Barnett C., Prestidge C.A. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. Mol Pharmacol 2010, 7(1):227-236.
12. Foraker A.B., Walczak R.J., Cohen M.H., Boiarski T.A., Grove C.F., Swaan P.W. Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers. Pharm Res 2003, 20(1):110-116.
13. Kilpelainen M., Riikonen J., Vlasova M.A., Huotari A., Lehto V.P., Salonen J., et al. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. J Control Release 2009, 137(2):166-170.
14. Heikkila T., Salonen J., Tuura J., Kumar N., Salmi T., Murzin D.Y., et al. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 2007, 14(6):337-347.
15. Tanaka T., Mangala L.S., Vivas-Mejia P.E., Nieves-Alicea R., Mann A.P., Mora E., et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010, 70(9):3687-3696.
16. Bimbo L.M., Sarparanta M., Santos H.A., Airaksinen A.J., Makila E., Laaksonen T., et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010, 4(6):3023-3032.
17. Choi J., Zhang Q., Reipa V., Wang N.S., Stratmeyer M.E., Hitchins V.M., et al. Comparison of cytotoxic and inflammatory responses of photoluminescent silicon nanoparticles with silicon micron-sized particles in RAW 264.7 macrophages. J Appl Toxicol 2009, 29(1):52-60.
18. Park J.H., Gu L., von Maltzahn G., Ruoslahti E., Bhatia S.N., Sailor M.J. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater 2009, 8(4):331-336.
19. Salonen J., Lehto V.-P., Laine E. Thermal oxidation of free-standing porous silicon films. Appl Phys Lett 1997, 70(5):637-639.
20. Santos H.A., Riikonen J., Salonen J., Makila E., Heikkila T., Laaksonen T., et al. In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. Acta Biomater 2010, 6(7):2721-2731.
21. Heikkila T., Santos H.A., Kumar N., Murzin D.Y., Salonen J., Laaksonen T., et al. Cytotoxicity study of ordered mesoporous silica MCM-41 and SBA-15 microparticles on Caco-2 cells. Eur J Pharm Biopharm 2010, 74(3):483-494.
22. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998, 15(5):698-705.
23. Vallet-Regi M., Balas F., Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed Engl 2007, 46(40):7548-7558.
24. Gupta A.K., Gupta M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 2005, 26(13):1565-1573.
25. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311(5761):622-627.
26. Chamberlain L.M., Godek M.L., Gonzalez-Juarrero M., Grainger D.W. Phenotypic non-equivalence of murine (monocyte-) macrophage cells in biomaterial and inflammatory models. J Biomed Mater Res A 2009, 88(4):858-871.
27. Jones C.F., Grainger D.W. In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev 2009, 61(6):438-456.
28. Ohsawa I., Ishikawa M., Takahashi K., Watanabe M., Nishimaki K., Yamagata K., et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 2007, 13(6):688-694.
29. Low S.P., Williams K.A., Canham L.T., Voelcker N.H. Generation of reactive oxygen species from porous silicon microparticles in cell culture medium. J Biomed Mater Res A 2010, 93(3):1124-1131.
30. Vignoli A.L., Srivastava R.C., Stammati A., Turco L., Tanori M., Zucco F. Nitric oxide production in Caco-2 cells exposed to different inducers, inhibitors and natural toxins. Toxicol In Vitro 2001, 15(4-5):289-295.
31. Salzman A.L., Menconi M.J., Unno N., Ezzell R.M., Casey D.M., Gonzalez P.K., et al. Nitric oxide dilates tight junctions and depletes ATP in cultured Caco-2BBe intestinal epithelial monolayers. Am J Phys 1995, 268(2 Pt 1):G361-G373.
32. Park E.J., Park K. Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro. Toxicol Lett 2009, 184(1):18-25.
33. Scheel J., Weimans S., Thiemann A., Heisler E., Hermann M. Exposure of the murine RAW 264.7 macrophage cell line to hydroxyapatite dispersions of various composition and morphology: assessment of cytotoxicity, activation and stress response. Toxicol In Vitro 2009, 23(3):531-538.
34. Kocbach A., Totlandsdal A.I., Lag M., Refsnes M., Schwarze P.E. Differential binding of cytokines to environmentally relevant particles: a possible source for misinterpretation of in vitro results?. Toxicol Lett 2008, 176(2):131-137.
35. Laaksonen T., Santos H., Vihola H., Salonen J., Riikonen J., Heikkila T., et al. Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles. Chem Res Toxicol 2007, 20(12):1913-1918.
36. Monteiro-Riviere N.A., Inman A.O., Zhang L.W. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol 2009, 234(2):222-235.
37. AshaRani P.V., Low Kah Mun G., Hande M.P., Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 2009, 3(2):279-290.
38. Niles A.L., Moravec R.A., Eric Hesselberth P., Scurria M.A., Daily W.J., Riss T.L. A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers. Anal Biochem 2007, 366(2):197-206.
39. Jiang W., Kim B.Y., Rutka J.T., Chan W.C. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008, 3(3):145-150.
40. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6(4):662-668.
41. Gratton S.E., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008, 105(33):11613-11618.
42. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377(Pt 1):159-169.
43. Chapekar M.S., Zaremba T.G., Kuester R.K., Hitchins V.M. Synergistic induction of tumor necrosis factor alpha by bacterial lipopolysaccharide and lipoteichoic acid in combination with polytetrafluoroethylene particles in a murine macrophage cell line RAW 264.7. J Biomed Mater Res 1996, 31(2):251-256.
44. Yin L., Ding J., He C., Cui L., Tang C., Yin C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 2009, 30(29):5691-5700.
45. Zhang Y., Zhi Z., Jiang T., Zhang J., Wang Z., Wang S. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control Release 2010, 145(3):257-263.
46. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991, 175(3):880-885.
47. Kaukonen A.M., Laitinen L., Salonen J., Tuura J., Heikkila T., Limnell T., et al. Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles. Eur J Pharm Biopharm 2007, 66(3):348-356.
48. Brouwers J., Brewster M.E., Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?. J Pharm Sci 2009, 98(8):2549-2572.